

**MEDICAL LABORATORY**

**EVALUATION**

**PARTICIPANT SUMMARY**

**2 • 0 • 2 • 1**

Medical Laboratory  
Evaluation 

Immunology  
2021 MLE-M3

# Table of Contents

<b>Evaluation Criteria .....</b>	<b>3</b>
<b>Immunology</b>	
<b>Infectious Mononucleosis.....</b>	<b>4</b>
<b>Rheumatoid Factor .....</b>	<b>6</b>
Qualitative .....	6
Semi-Quantitative (Titer).....	7
Quantitative (IU) .....	8
<b>Anti-Streptolysin O (ASO).....</b>	<b>8</b>
<b>Complement C3 .....</b>	<b>9</b>
<b>Complement C4 .....</b>	<b>10</b>
<b>IgA .....</b>	<b>11</b>
<b>IgG .....</b>	<b>11</b>
<b>IgM.....</b>	<b>12</b>
<b>C-Reactive Protein, Regular .....</b>	<b>12</b>
Qualitative .....	12
Quantitative .....	13
<b>C-Reactive Protein, High Sensitivity .....</b>	<b>13</b>
<b>Antinuclear Antibody .....</b>	<b>14</b>
Qualitative .....	14
Semi-Quantitative (Titer).....	15
<b>Anti-dsDNA .....</b>	<b>16</b>
<b>Anti-RNP .....</b>	<b>16</b>
<b>Anti-RNP/Sm .....</b>	<b>17</b>
<b>Anti-SSA.....</b>	<b>17</b>
<b>Anti-SSB.....</b>	<b>18</b>
<b>Anti-SSA/SSB .....</b>	<b>18</b>
<b>Anti-Sm .....</b>	<b>18</b>
<b>Rubella .....</b>	<b>19</b>
Qualitative .....	19
Quantitative .....	19
<b>Anti-HIV .....</b>	<b>19</b>
<b>Allergen Specific IgE Antibodies.....</b>	<b>20</b>
<b>Total IgE .....</b>	<b>22</b>
<b>Syphilis Serology .....</b>	<b>23</b>
Qualitative: Treponema pallidum antibodies .....	23
Qualitative: RPR .....	23
Semi-Quantitative: RPR (Titer) .....	24
<b>H. pylori Antibody Detection .....</b>	<b>25</b>
<b>Mycoplasma Antibody .....</b>	<b>25</b>
<b>SARS-CoV-2 Serology.....</b>	<b>25</b>
<b>Viral Markers.....</b>	<b>26</b>
Anti-HBc (IgM) .....	26
Anti-HBc (Total/IgG) .....	26
Anti-HIV .....	27
Anti-HAV (IgM) .....	27
Anti-HAV (Total/IgG).....	28
HBeAg.....	28
Anti-HBs .....	28
HBsAg .....	29
Anti-HCV .....	29

## Evaluation Criteria

The evaluation criteria used in the MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative/semi-quantitative procedures, evaluation is based on participant or referee consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Anti-dsDNA	80% Participant Consensus
Anti-HIV	80% Participant Consensus
Antinuclear Antibody (ANA)	80% Participant Consensus
Anti-RNP	80% Participant Consensus
Anti-RNP/Sm	80% Participant Consensus
Anti-Sm	80% Participant Consensus
Anti-SSA	80% Participant Consensus
Anti-SSA/SSB	80% Participant Consensus
Anti-SSB	80% Participant Consensus
Anti-Streptolysin O (ASO)	80% Participant Consensus
C-Reactive Protein	80% Participant Consensus
Diagnostic Allergy	80% Participant Consensus
H. <i>pylori</i> Antibody Detection	80% Participant Consensus
Infectious Mononucleosis	80% Participant Consensus
Mycoplasma Antibody	80% Participant Consensus
Rheumatoid Factor	80% Participant Consensus
Rubella Antibody	80% Participant Consensus
SARS-CoV-2 Serology	80% Participant Consensus
Syphilis Serology	80% Participant Consensus
Viral Markers	80% Participant Consensus

### Semi-Quantitative

Antinuclear Antibody (ANA) Titer	80% Participant Consensus
Anti-Streptolysin O (ASO) Titer	80% Participant Consensus
Rheumatoid Factor (Titer)	80% Participant Consensus
RPR Titer	80% Participant Consensus
VDRL Titer	80% Participant Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 10 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on page 37 under the heading "Acceptable Ranges for Quantitative Results."

Complement C3	$\pm 3$ SD
Complement C4	$\pm 3$ SD
C-Reactive Protein	$\pm 30\%$ or $2$ SD*
High Sensitivity C-Reactive Protein	$\pm 30\%$ or $1$ mg/L*
Rheumatoid Factor (International Units)	$\pm 3$ SD
Rubella (International Units)	$\pm 3$ SD
Total IgA	$\pm 3$ SD
Total IgE	$\pm 3$ SD
Total IgG	$\pm 25\%$
Total IgM	$\pm 3$ SD

\*Whichever is greater

## Infectious Mononucleosis

<u>Method</u>	<u>Specimen IM-11</u>		<u>Specimen IM-12</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	108	107	1
Alere Clearview - moderate	-	1	1	-
Alere Clearview - waived	-	4	4	-
Alere Clearview Mono Plus II - moderate	-	1	1	-
Alere Clearview Mono Plus II - waived	-	3	3	-
BioStar Acceava Mono Test	-	1	1	-
BioStar Acceava Mono-whole bld	-	3	3	-
Cardinal Health SP Brand	-	1	1	-
Cardinal Health SP Brand - waived	-	4	4	-
Clarity Diagnostics	-	1	1	-
Consult Diagnostics - moderate	-	3	3	-
Consult Diagnostics - waived	-	15	15	-
Fisher HealthCare Sure-Vue	-	2	2	-
Henry Schein OneStep+ - moderate	-	1	1	-
Henry Schein OneStep+ - waived	-	10	10	-
Immunostics Inc.	-	1	1	-
LifeSign Status - waived	-	6	6	-
Other Waived method	-	6	6	-
Quidel QuickVue+	-	1	1	-
Quidel QuickVue+ - waived	-	2	1	1
Sekisui OSOM	-	4	4	-
Sekisui OSOM (waived)	-	38	38	-

## Infectious Mononucleosis

<u>Method</u>	Specimen IM-13		Specimen IM-14		Specimen IM-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	21	-	21	21	-
Alere Clearview - moderate	-	1	-	1	1	-
Alere Clearview Mono Plus II - moderate	-	1	-	1	1	-
Alere Clearview Mono Plus II - waived	-	1	-	1	1	-
BioStar Aceava Mono Test	-	1	-	1	1	-
Consult Diagnostics - moderate	-	1	-	1	1	-
Consult Diagnostics - waived	-	1	-	1	1	-
Fisher HealthCare Sure-Vue	-	1	-	1	1	-
Henry Schein OneStep+ - moderate	-	1	-	1	1	-
Henry Schein OneStep+ - waived	-	2	-	2	2	-
LifeSign Status - waived	-	1	-	1	1	-
Other Waived method	-	2	-	2	2	-
Quidel QuickVue+	-	1	-	1	1	-
Quidel QuickVue+ - waived	-	1	-	1	1	-
Sekisui OSOM	-	4	-	4	4	-
Sekisui OSOM (waived)	-	2	-	2	2	-

## Rheumatoid Factor—Qualitative

<b><u>Method</u></b>	<b>Specimen RF-11</b>		<b>Specimen RF-12</b>		<b>Specimen RF-13</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	17	-	17	-	-	17
ASI	4	-	4	-	-	4
Biokit Rheumajet	1	-	1	-	-	1
Fisher HealthCare Sure-Vue	2	-	2	-	-	2
Phadia EliA	1	-	1	-	-	1
Stanbio Laboratory	4	-	4	-	-	4
TheraTest	4	-	4	-	-	4
Wampole Rheumatex	1	-	1	-	-	1

<b><u>Method</u></b>	<b>Specimen RF-14</b>		<b>Specimen RF-15</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	17	-	-	17
ASI	4	-	-	4
Biokit Rheumajet	1	-	-	1
Fisher HealthCare Sure-Vue	2	-	-	2
Phadia EliA	1	-	-	1
Stanbio Laboratory	4	-	-	4
TheraTest	4	-	-	4
Wampole Rheumatex	1	-	-	1

**Rheumatoid Factor—Semi-Quantitative (Titer)**

<u>Specimen/Method</u>	<u>N/A (Neg)</u>	<u>2/4</u>	<u>8/10</u>	<u>16/20</u>	<u>32/40</u>	<u>64/80</u>	<u>128/160</u>	<u>256/320</u>	<u>512/640</u>	<u>1024/1280</u>	<u>2048/2560</u>	<u>&gt;2560</u>
<b>Specimen RF-11</b>												
ALL METHODS	-	-	5	-	-	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	-	5	-	-	-	-	-	-	-	-	-
<b>Specimen RF-12</b>												
ALL METHODS	-	5	-	-	-	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	5	-	-	-	-	-	-	-	-	-	-
<b>Specimen RF-13</b>												
ALL METHODS	5	-	-	-	-	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	5	-	-	-	-	-	-	-	-	-	-	-
<b>Specimen RF-14</b>												
ALL METHODS	-	2	3	-	-	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	2	3	-	-	-	-	-	-	-	-	-
<b>Specimen RF-15</b>												
ALL METHODS	5	-	-	-	-	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	5	-	-	-	-	-	-	-	-	-	-	-

## Rheumatoid Factor—Quantitative (IU/mL)

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen RF-11</b>						
All Method	16	118.3	5.0	4.2	122	103 - 134
Beckman AU	10	118.8	5.0	4.2	120	103 - 134
<b>Specimen RF-12</b>						
All Method	16	64.3	2.9	4.5	66	55 - 73
Beckman AU	10	64.0	2.0	3.1	65	58 - 70
<b>Specimen RF-13</b>						
All Method	15	7.5	5.2	69.1	3	0 - 24
Beckman AU	9	-	-	-	7	0 - 24
<b>Specimen RF-14</b>						
All Method	16	64.0	3.1	4.9	66	54 - 74
Beckman AU	10	63.8	3.1	4.9	65	54 - 74
<b>Specimen RF-15</b>						
All Method	16	6.4	5.7	88.5	2	0 - 24
Beckman AU	10	4.6	5.1	110.4	3	0 - 20

## Anti-Streptolysin O (ASO)—Qualitative

<u>Method</u>	<b>Specimen AS-11</b>		<b>Specimen AS-12</b>		<b>Specimen AS-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	5	5	-	5	-
ASI	-	5	5	-	5	-
<u>Method</u>	<b>Specimen AS-14</b>		<b>Specimen AS-15</b>			
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>		
ALL METHODS	-	5	-	5		
ASI	-	5	-	5		



**Complement C3 (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-11</b>						
All Method	14	33.6	4.7	14.1	33	19 - 48
Beckman AU	10	34.3	3.8	11.0	33	23 - 46
<b>Specimen IMP-12</b>						
All Method	14	147.2	6.2	4.2	149	128 - 166
Beckman AU	10	146.0	5.7	3.9	147	129 - 163
<b>Specimen IMP-13</b>						
All Method	14	34.2	4.8	13.9	33	19 - 49
Beckman AU	10	35.2	3.8	10.9	34	23 - 47
<b>Specimen IMP-14</b>						
All Method	14	144.3	6.7	4.6	146	124 - 165
Beckman AU	10	142.7	5.1	3.6	144	127 - 158
<b>Specimen IMP-15</b>						
All Method	14	218.3	6.8	3.1	217	197 - 239
Beckman AU	10	216.8	4.5	2.1	216	203 - 231

## Complement C4 (mg/dL)

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-11</b>						
All Method	14	6.0	1.6	26.4	5	1 - 11
Beckman AU	10	6.2	1.5	23.9	6	1 - 11
<b>Specimen IMP-12</b>						
All Method	14	25.6	1.9	7.6	26	19 - 32
Beckman AU	10	26.3	1.0	3.9	26	23 - 30
<b>Specimen IMP-13</b>						
All Method	14	6.7	1.2	18.4	7	2 - 11
Beckman AU	10	7.0	0.9	12.8	7	4 - 10
<b>Specimen IMP-14</b>						
All Method	14	23.9	2.3	9.6	25	16 - 31
Beckman AU	10	24.8	1.1	4.4	25	21 - 29
<b>Specimen IMP-15</b>						
All Method	14	36.4	2.7	7.5	38	28 - 45
Beckman AU	10	37.7	1.4	3.6	38	33 - 42

**IgA (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-11</b>						
All Method	10	45.6	4.7	10.4	44	31 - 60
<b>Specimen IMP-12</b>						
All Method	10	523.0	18.6	3.6	524	467 - 579
<b>Specimen IMP-13</b>						
All Method	10	37.4	4.4	11.7	39	24 - 51
<b>Specimen IMP-14</b>						
All Method	10	230.8	12.3	5.3	231	193 - 268
<b>Specimen IMP-15</b>						
All Method	10	342.8	16.8	4.9	341	292 - 394

**IgG (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-11</b>						
All Method	10	236.6	21.7	9.2	238	177 - 296
<b>Specimen IMP-12</b>						
All Method	10	1084.4	57.7	5.3	1064	813 - 1356
<b>Specimen IMP-13</b>						
All Method	10	218.4	30.0	13.8	211	163 - 273
<b>Specimen IMP-14</b>						
All Method	10	1997.0	132.0	6.6	1985	1497 - 2497
<b>Specimen IMP-15</b>						
All Method	10	1711.8	87.0	5.1	1683	1283 - 2140

**IgM (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-11</b>						
All Method	10	23.0	1.6	6.9	23	18 - 28
<b>Specimen IMP-12</b>						
All Method	10	106.2	9.8	9.2	102	76 - 136
<b>Specimen IMP-13</b>						
All Method	10	20.8	2.4	11.5	20	13 - 28
<b>Specimen IMP-14</b>						
All Method	10	107.4	9.3	8.7	103	79 - 136
<b>Specimen IMP-15</b>						
All Method	10	158.6	15.9	10.1	152	110 - 207

**C-Reactive Protein—Qualitative, Regular**

<u>Method</u>	<u>Specimen CR-5</u>		<u>Specimen CR-6</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	4	-	-	4
Siemens Dimension	4	-	-	4

**C-Reactive Protein—Quantitative (mg/dL or mg/L), Regular**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen CR-5</b>						
All Method mg/dL - units	27	15.274	13.491	88.3	3.10	0.00 - 42.26
Beckman AU	5	2.740	0.358	13.1	2.80	1.91 - 3.57
All Immunology Methods mg/L - units	14	2.680	0.335	12.5	2.70	1.87 - 3.49
All Immunology Methods	13	28.838	3.146	10.9	27.00	20.18 - 37.49

**Specimen CR-6**

All Method mg/dL - units	23	0.300	0.456	151.7	0.20	0.00 - 1.22
Beckman AU	5	0.162	0.193	119.1	0.10	0.00 - 0.55
All Immunology Methods mg/L - units	14	0.155	0.135	86.9	0.15	0.00 - 0.43
All Immunology Methods	12	1.420	1.838	129.4	0.65	0.00 - 5.10

**C-Reactive Protein—Quantitative (mg/L), High Sensitivity**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen HCR-5</b>						
All Method	18	11.522	1.347	11.7	11.53	8.06 - 14.98
Beckman AU	5	12.446	1.561	12.5	11.43	8.71 - 16.18
<b>Specimen HCR-6</b>						
All Method	18	0.898	0.411	45.8	0.89	0.00 - 1.90
Beckman AU	4	-	-	-	0.92	0.15 - 2.16

## Antinuclear Antibody (ANA) - Qualitative

<b><u>Method</u></b>	<b>Specimen AE-11</b>		<b>Specimen AE-12</b>		<b>Specimen AE-13</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	11	10	1	11	-
ASI	-	1	-	1	1	-
Bio-Rad	-	1	1	-	1	-
GenBio ImmunoDOT Panel 1	-	1	1	-	1	-
Immuno Concepts	-	2	2	-	2	-
INOVA Diagnostics	-	2	2	-	2	-
TheraTest	-	4	4	-	4	-

<b><u>Method</u></b>	<b>Specimen AE-14</b>		<b>Specimen AE-15</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	11	-	11
ASI	-	1	-	1
Bio-Rad	-	1	-	1
GenBio ImmunoDOT Panel 1	-	1	-	1
Immuno Concepts	-	2	-	2
INOVA Diagnostics	-	2	-	2
TheraTest	-	4	-	4

**Antinuclear Antibody (ANA)—Semi-Quantitative (Titer)**

<u>Specimen/Method</u>	<u>N/A</u> <u>(Neg)</u>	<u>8/</u> <u>10</u>	<u>16/</u> <u>20</u>	<u>32/</u> <u>40</u>	<u>64/</u> <u>80</u>	<u>128/</u> <u>160</u>	<u>256/</u> <u>320</u>	<u>512/</u> <u>640</u>	<u>&gt;640</u>	<u>1024/</u> <u>1280</u>	<u>2048/</u> <u>2560</u>	<u>≥2560</u>
<b>Specimen AE-11</b>												
ALL METHODS	5	-	-	-	-	-	-	-	-	-	-	-
Bio-Rad	1	-	-	-	-	-	-	-	-	-	-	-
Immuno Concepts	2	-	-	-	-	-	-	-	-	-	-	-
INOVA Diagnostics	2	-	-	-	-	-	-	-	-	-	-	-
<b>Specimen AE-12</b>												
ALL METHODS	-	-	-	-	-	1	2	1	-	1	-	-
Bio-Rad	-	-	-	-	-	-	1	-	-	-	-	-
Immuno Concepts	-	-	-	-	-	1	1	-	-	-	-	-
INOVA Diagnostics	-	-	-	-	-	-	-	1	-	1	-	-
<b>Specimen AE-13</b>												
ALL METHODS	-	-	-	-	-	-	1	3	-	1	-	-
Bio-Rad	-	-	-	-	-	-	-	1	-	-	-	-
Immuno Concepts	-	-	-	-	-	-	-	1	-	1	-	-
INOVA Diagnostics	-	-	-	-	-	-	1	1	-	-	-	-
<b>Specimen AE-14</b>												
ALL METHODS	5	-	-	-	-	-	-	-	-	-	-	-
Bio-Rad	1	-	-	-	-	-	-	-	-	-	-	-
Immuno Concepts	2	-	-	-	-	-	-	-	-	-	-	-
INOVA Diagnostics	2	-	-	-	-	-	-	-	-	-	-	-
<b>Specimen AE-15</b>												
ALL METHODS	5	-	-	-	-	-	-	-	-	-	-	-
Bio-Rad	1	-	-	-	-	-	-	-	-	-	-	-
Immuno Concepts	2	-	-	-	-	-	-	-	-	-	-	-
INOVA Diagnostics	2	-	-	-	-	-	-	-	-	-	-	-

## Anti-dsDNA

<u>Method</u>	<u>Specimen AE-11</u>		<u>Specimen AE-12</u>		<u>Specimen AE-13</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	7	6	1	1	6
GenBio ImmunoDOT Panel 1	-	1	-	1	1	-
Immuno Concepts	-	1	1	-	-	1
Phadia EliA	-	1	1	-	-	1
TheraTest	-	4	4	-	-	4

<u>Method</u>	<u>Specimen AE-14</u>		<u>Specimen AE-15</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	7	-	7
GenBio ImmunoDOT Panel 1	-	1	-	1
Immuno Concepts	-	1	-	1
Phadia EliA	-	1	-	1
TheraTest	-	4	-	4

## Anti-RNP

<u>Method</u>	<u>Specimen AE-11</u>		<u>Specimen AE-12</u>		<u>Specimen AE-13</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	2	-	2	2	-
Immuno Concepts	-	1	-	1	1	-
Phadia EliA	-	1	-	1	1	-

<u>Method</u>	<u>Specimen AE-14</u>		<u>Specimen AE-15</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	2	-	2
Immuno Concepts	-	1	-	1
Phadia EliA	-	1	-	1



## Anti-RNP/Sm

<u>Method</u>	Specimen AE-11		Specimen AE-12		Specimen AE-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	4	2	6	-
GenBio ImmunoDOT Panel 1	-	1	-	1	1	-
Immuno Concepts	-	1	-	1	1	-
TheraTest	-	4	4	-	4	-

<u>Method</u>	Specimen AE-14		Specimen AE-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
GenBio ImmunoDOT Panel 1	-	1	-	1
Immuno Concepts	-	1	-	1
TheraTest	-	4	-	4

## Anti-SSA

<u>Method</u>	Specimen AE-11		Specimen AE-12		Specimen AE-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	6	-	-	6
Immuno Concepts	-	1	1	-	-	1
Phadia EliA	-	1	1	-	-	1
TheraTest	-	4	4	-	-	4

<u>Method</u>	Specimen AE-14		Specimen AE-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
Immuno Concepts	-	1	-	1
Phadia EliA	-	1	-	1
TheraTest	-	4	-	4

**Anti-SSB**

<u>Method</u>	Specimen AE-11		Specimen AE-12		Specimen AE-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6	-	6
Immuno Concepts	-	1	-	1	-	1
Phadia EliA	-	1	-	1	-	1
TheraTest	-	4	-	4	-	4

<u>Method</u>	Specimen AE-14		Specimen AE-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
Immuno Concepts	-	1	-	1
Phadia EliA	-	1	-	1
TheraTest	-	4	-	4

**Anti-SSA/SSB**

<u>Method</u>	Specimen AE-11		Specimen AE-12		Specimen AE-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	1	1	-	-	1
GenBio ImmunodOT Panel 1	-	1	1	-	-	1

<u>Method</u>	Specimen AE-14		Specimen AE-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	1	-	1
GenBio ImmunodOT Panel 1	-	1	-	1

**Anti-Sm**

<u>Method</u>	Specimen AE-11		Specimen AE-12		Specimen AE-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6	-	6
Immuno Concepts	-	1	-	1	-	1
Phadia EliA	-	1	-	1	-	1
TheraTest	-	4	-	4	-	4

<u>Method</u>	Specimen AE-14		Specimen AE-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
Immuno Concepts	-	1	-	1
Phadia EliA	-	1	-	1
TheraTest	-	4	-	4

## Rubella—Qualitative

<u>Method</u>	Specimen RU-11		Specimen RU-12		Specimen RU-13	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	5	-	5	-	-	5
Siemens ADVIA Centaur	5	-	5	-	-	5

<u>Method</u>	Specimen RU-14		Specimen RU-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	5	-	-	5
Siemens ADVIA Centaur	5	-	-	5

## Rubella—Quantitative (IU/mL)

One lab reported results for Rubella – Quantitative (IU/mL). The vendor assay values on a Beckman Access 2 for specimens RU-11 through RU-15 are: 38.3 IU/mL, 57.2 IU/mL, <10.0 IU/mL, 38.3 IU/mL, and <10.0 IU/mL, respectively.

## Anti-HIV

<u>Method</u>	Specimen HIV-11		Specimen HIV-12	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	62	62	-
Alere Clearview HIV1/2 STAT-PAK	-	2	2	-
Alere Determine - moderate	-	2	2	-
Alere Determine - waived	-	15	15	-
bioLytical Labs INSTI HIV - moderate	-	2	2	-
bioLytical Labs INSTI HIV - waived	-	11	11	-
Chembio HIV 1/2 Assay - waived	-	13	13	-
Orasure OraQuick Advance Rapid HIV-1/2 - waived	-	14	14	-
Other Waived method	-	3	3	-

<u>Method</u>	Specimen HIV-13		Specimen HIV-14		Specimen HIV-15	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	5	5	-	-	5
bioLytical Labs INSTI HIV - moderate	-	5	5	-	-	5

## Allergen Specific IgE Antibodies

### Specimen AL-11

<u>Method</u>	Bahia Grass (g17) Allergen								Meadow, Kentucky Blue, June Grass (g8) Allergens							
	CLASS RESULT								CLASS RESULT							
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	-	2	1	-	-	-	-	-	-	2	1	-	-	-
Hitachi CLA-1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia ImmunoCAP System (KU/L)	-	-	-	2	1	-	-	-	-	-	-	2	1	-	-	-

<u>Method</u>	Alternaria alternata (m6) Allergen								Walnut (f256) Allergen							
	CLASS RESULT								CLASS RESULT							
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	2	2	-	-	-	-	-	-	1	2	-	-	-	-
Hitachi CLA-1	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia ImmunoCAP System (KU/L)	-	-	-	2	-	-	-	-	-	-	1	2	-	-	-	-

<u>Method</u>	Hazelnut (f17) Allergen								Lobster (f80) Allergen							
	CLASS RESULT								CLASS RESULT							
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	1	2	-	-	-	-	-	1	1	2	-	-	-	-
Hitachi CLA-1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia ImmunoCAP System (KU/L)	-	-	1	2	-	-	-	-	-	1	1	2	-	-	-	-

<u>Method</u>	Cat Epithelium (e1) Allergen							
	CLASS RESULT							
	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	-	1	1	2	-	-
Hitachi CLA-1	-	-	-	-	-	2	-	-
Phadia ImmunoCAP System (KU/L)	-	-	-	1	1	-	-	-

# Allergen Specific IgE Antibodies

## Specimen AL-12

<b><u>Method</u></b>	<b>Silver Birch Tree (t3) Allergen</b>								<b>White Oak (t7) Allergen</b>								
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>								
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6	
ALL METHODS	-	-	1	3	-	-	-	-	-	-	-	-	2	1	-	-	-
Hitachi CLA-1	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia ImmunoCAP System (KU/L)	-	-	1	2	-	-	-	-	-	-	-	-	2	1	-	-	-
	<b>House Dust Mite (D. farinae) (d2) Allergen</b>								<b>Dog Dander (e5) Allergen</b>								
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>								
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6	
ALL METHODS	-	-	-	2	1	-	-	-	1	1	1	2	-	-	-	-	
Hitachi CLA-1	-	-	-	-	1	-	-	-	1	-	-	-	-	-	-	-	
Phadia ImmunoCAP System (KU/L)	-	-	-	2	-	-	-	-	-	1	1	2	-	-	-	-	
	<b>Penicillium chrysogenum (m1) Allergen</b>								<b>Orchard Grass (Cocksfoot) (g3) Allergen</b>								
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>								
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6	
ALL METHODS	2	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hitachi CLA-1	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phadia ImmunoCAP System (KU/L)	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	<b>Timothy Grass (g6) Allergen</b>																
	<b>CLASS RESULT</b>																
	0	0/1	1	2	3	4	5	6									
ALL METHODS	-	-	-	-	2	2	-	-									
Hitachi CLA-1	-	-	-	-	-	2	-	-									
Phadia ImmunoCAP System (KU/L)	-	-	-	-	2	-	-	-									

**Total IgE—Quantitative (U/mL)**

<b><u>Specimen/Method</u></b>	<b><u>Labs</u></b>	<b><u>Mean</u></b>	<b><u>SD</u></b>	<b><u>CV</u></b>	<b><u>Median</u></b>	<b><u>Range</u></b>
<b>Specimen AL-11</b>						
All Method	5	369.7	5.5	1.5	370	353 - 387
<b>Specimen AL-12</b>						
All Method	5	364.0	19.7	5.4	367	304 - 424
<b>Specimen AL-13</b>						
All Method	5	6.7	0.6	8.7	7	4 - 9
<b>Specimen AL-14</b>						
All Method	5	18.0	1.0	5.6	18	15 - 21
<b>Specimen AL-15</b>						
All Method	5	70.7	5.1	7.3	72	55 - 87

**Syphilis Serology—Qualitative: MHA-TP**

<u>Method</u>	Specimen SY-11		Specimen SY-12		Specimen SY-13	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	-	-	-	-	-

  

<u>Method</u>	Specimen SY-14		Specimen SY-15	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	-	-	-

**Syphilis Serology—Qualitative: Treponema pallidum antibodies**

<u>Method</u>	Specimen SY-11		Specimen SY-12		Specimen SY-13	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	8	8	-	8	-
diagnostics direct Syphilis Health Check	-	6	6	-	6	-
Siemens ADVIA	-	2	2	-	2	-

  

<u>Method</u>	Specimen SY-14		Specimen SY-15	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	8	8	-
diagnostics direct Syphilis Health Check	-	6	6	-
Siemens ADVIA Centaur	-	2	2	-

**Syphilis Serology—Qualitative: RPR**

<u>Method</u>	Specimen SY-11		Specimen SY-12		Specimen SY-13	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	10	10	-	10	-
ASI	-	5	5	-	5	-
Becton Dickinson	-	2	2	-	2	-
Fisher HealthCare Sure-Vue	-	3	3	-	3	-

  

<u>Method</u>	Specimen SY-14		Specimen SY-15	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	10	10	-
ASI	-	5	5	-
Becton Dickinson	-	2	2	-
Fisher HealthCare Sure-Vue	-	3	3	-

**Syphilis Serology—Semi-Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>N/A (Neg)</u>	<u>1:1</u>	<u>1:2</u>	<u>1:4</u>	<u>1:8</u>	<u>1:16</u>	<u>1:32</u>	<u>1:64</u>	<u>1:&gt;64</u>
<b>Specimen SY-11</b>									
ALL METHODS	4	-	-	-	-	-	-	-	-
ASI	2	-	-	-	-	-	-	-	-
Becton Dickinson	1	-	-	-	-	-	-	-	-
<b>Specimen SY-12</b>									
ALL METHODS	-	-	-	2	2	-	-	-	-
ASI	-	-	-	1	1	-	-	-	-
Becton Dickinson	-	-	-	-	1	-	-	-	-
<b>Specimen SY-13</b>									
ALL METHODS	-	-	2	2	-	-	-	-	-
ASI	-	-	1	1	-	-	-	-	-
Becton Dickinson	-	-	-	1	-	-	-	-	-
<b>Specimen SY-14</b>									
ALL METHODS	4	-	-	-	-	-	-	-	-
ASI	2	-	-	-	-	-	-	-	-
Becton Dickinson	1	-	-	-	-	-	-	-	-
<b>Specimen SY-15</b>									
ALL METHODS	-	-	2	1	1	-	-	-	-
ASI	-	-	-	1	1	-	-	-	-
Becton Dickinson	-	-	1	-	-	-	-	-	-



## H. pylori Antibody Detection

<u>Method</u>	<u>Specimen HP-5</u>		<u>Specimen HP-6</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	25	24	1
Alere Clearview - moderate	-	2	2	-
Alere Clearview - waived	-	1	1	-
Alfa Scientific Instant-View	-	2	2	-
Consult Diagnostics - moderate	-	1	1	-
Henry Schein OneStep+ - moderate	-	1	1	-
Henry Schein OneStep+ - waived	-	7	6	1
McKesson Medi-Lab Performance - waived	-	4	4	-
NDC Pro Advantage	-	1	1	-
Polymedco Poly stat	-	1	1	-
Quidel QuickVue	-	1	1	-
Sekisui OSOM	-	4	4	-

## Mycoplasma Antibody

<u>Method</u>	<u>Specimen MY-5</u>		<u>Specimen MY-6</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	1	4	5	-
Meridian ImmunoCard	1	4	5	-

## SARS-CoV-2 Serology

<u>Method</u>	<u>Specimen SAB-5</u>		<u>Specimen SAB-6</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	16	-	-	16
Abbott Alinity	1	-	-	1
Abbott Architect	2	-	-	2
Access Bio CareStart	2	-	-	2
Beckman ACCESS / 2 / Dxl	3	-	-	3
Healgen Scientific	2	-	-	2
Roche cobas 6000 / e 601	1	-	-	1
Roche cobas e 411	2	-	-	2
Siemens ADVIA	1	-	-	1
Sienna-Clarity COVIBLOCK	1	-	-	1
VITROS Eci	1	-	-	1

**Viral Markers – Anti-HBc (IgM)**

<b><u>Method</u></b>	<b>Specimen VM-11</b>			<b>Specimen VM-12</b>			<b>Specimen VM-13</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	5	-	-	-	5	-
Abbott Alinity	-	3	-	3	-	-	-	3	-
Abbott Architect	-	1	-	1	-	-	-	1	-
VITROS 5600	-	1	-	1	-	-	-	1	-

<b><u>Method</u></b>	<b>Specimen VM-14</b>			<b>Specimen VM-15</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	-	5	-
Abbott Alinity	-	3	-	-	3	-
Abbott Architect	-	1	-	-	1	-
VITROS 5600	-	1	-	-	1	-

**Viral Markers – Anti-HBc (Total/IgG)**

<b><u>Method</u></b>	<b>Specimen VM-11</b>			<b>Specimen VM-12</b>			<b>Specimen VM-13</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	5	-	-	-	5	-
Abbott Alinity	-	3	-	3	-	-	-	3	-
Roche cobas 6000 / e 601	-	2	-	2	-	-	-	2	-

<b><u>Method</u></b>	<b>Specimen VM-14</b>			<b>Specimen VM-15</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	5	-	-
Abbott Alinity	-	3	-	3	-	-
Roche cobas 6000 / e 601	-	2	-	2	-	-

## Viral Markers – Anti-HIV

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	6	-	-	6	-	-	6	-
Abbott Alinity	-	2	-	-	2	-	-	2	-
Abbott Architect	-	1	-	-	1	-	-	1	-
Orasure OraQuick									
Advance Rapid HIV-1/2 - waived	-	2	-	-	2	-	-	2	-
Siemens ADVIA	-	1	-	-	1	-	-	1	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	6	-	-	-	6	-
Abbott Alinity	2	-	-	-	2	-
Abbott Architect	1	-	-	-	1	-
Orasure OraQuick						
Advance Rapid HIV-1/2 - waived	2	-	-	-	2	-
Siemens ADVIA	1	-	-	-	1	-

## Viral Markers – Anti-HAV (IgM)

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	5	-	-	5	-	-	5	-
Abbott Alinity	-	1	-	-	1	-	-	1	-
Abbott Architect	-	1	-	-	1	-	-	1	-
Roche cobas 6000 / e 601	-	2	-	-	2	-	-	2	-
VITROS 5600	-	1	-	-	1	-	-	1	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	5	-	-	5	-
Abbott Alinity	-	1	-	-	1	-
Abbott Architect	-	1	-	-	1	-
Roche cobas 6000 / e 601	-	2	-	-	2	-
VITROS 5600	-	1	-	-	1	-

### Viral Markers – Anti-HAV (Total/IgG)

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	5	-	-	-	5	-	-	5	-
Abbott Architect	3	-	-	-	3	-	-	3	-
Siemens ADVIA	2	-	-	-	2	-	-	2	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	5	-	-	-	5	-
Abbott Architect	3	-	-	-	3	-
Siemens ADVIA	2	-	-	-	2	-

### Viral Markers – HBeAg

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	5	-	1	4	-	-	5	-
Abbott Architect	-	2	-	-	2	-	-	2	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	5	-	1	4	-
Abbott Architect	-	2	-	-	2	-

### Viral Markers – Anti-HBs

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	5	-	-	-	5	-	-	5	-
Abbott Alinity	2	-	-	-	2	-	-	2	-
Abbott Architect	1	-	-	-	1	-	-	1	-
Roche cobas 6000 / e 601	1	-	-	-	1	-	-	1	-
Siemens ADVIA	1	-	-	-	1	-	-	1	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	5	-	-	-	5	-
Abbott Alinity	2	-	-	-	2	-
Abbott Architect	1	-	-	-	1	-
Roche cobas 6000 / e 601	1	-	-	-	1	-
Siemens ADVIA	1	-	-	-	1	-

## Viral Markers – HBsAg

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	7	-	7	-	-	1	5	1
Abbott Alinity	-	2	-	2	-	-	1	1	-
Abbott Architect	-	1	-	1	-	-	-	1	-
Roche cobas 6000 / e 601	-	1	-	1	-	-	-	-	1
Siemens ADVIA	-	2	-	2	-	-	-	2	-
VITROS 5600	-	1	-	1	-	-	-	1	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	7	-	7	-	-
Abbott Alinity	-	2	-	2	-	-
Abbott Architect	-	1	-	1	-	-
Roche cobas 6000 / e 601	-	1	-	1	-	-
Siemens ADVIA	-	2	-	2	-	-
VITROS 5600	-	1	-	1	-	-

## Viral Markers – Anti-HCV

<u>Method</u>	<u>Specimen VM-11</u>			<u>Specimen VM-12</u>			<u>Specimen VM-13</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	2	9	-	-	11	-	-	11	-
Abbott Alinity	-	2	-	-	2	-	-	2	-
Abbott Architect	-	1	-	-	1	-	-	1	-
OraSure OraQuick HCV	-	2	-	-	2	-	-	2	-
Roche cobas 6000 / e 601	1	-	-	-	1	-	-	1	-
Roche cobas e 411	1	-	-	-	1	-	-	1	-
Siemens ADVIA	-	3	-	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-	-	1	-

<u>Method</u>	<u>Specimen VM-14</u>			<u>Specimen VM-15</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	11	-	-	11	-
Abbott Alinity	-	2	-	-	2	-
Abbott Architect	-	1	-	-	1	-
OraSure OraQuick HCV	-	2	-	-	2	-
Roche cobas 6000 / e 601	-	1	-	-	1	-
Roche cobas e 411	-	1	-	-	1	-
Siemens ADVIA	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-

## Medical Laboratory Evaluation

25 Massachusetts Ave NW Ste 700

Washington, DC 20001-7401

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

[www.acponline.org/mle](http://www.acponline.org/mle)